Showing 1 - 2 results of 2 for search 'I. Isufi', query time: 0.02s Refine Results
  1. 1
    P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

    P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOG... by E. Joffe, G. Nowakowski, H. Tun, A. Rosenthal, M. Lunning, R. Ramchandren, C.-C. Li, L. Zhou, E. Martinez, R. von Roemeling, R. Earhart, M. McMahon, I. Isufi, L. Leslie

    Published 2022-06-01
    Get full text
    Article
  2. 2
    P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

    P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA by C. Y. Cheah, N. L. Bartlett, S. Assouline, S. J. Schuster, W. Seog Kim, M. Shadman, I. Isufi, S. Yin, M. Y. Doral, J. Sit, V. Chen, H. Huang, M. Zhou, M. C. Wei, L. E. Budde

    Published 2022-06-01
    Get full text
    Article

Search Tools: